Last checked at 7 Dec 2021 07:00
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Update on AGM
Cambridge, UK, 07 December 2021 - Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, provides an update on its Annual General Meeting ("AGM") in response to the recent emergence of the omicron variant of the SARS-CoV-2 virus. In addition to the planned in-person meeting at 10.00 a.m. on 16 December 2021 at The City Centre, 80 Basinghall Street, London EC2V 5AG, the AGM will now also be relayed as a live webcast via the Investor Meet Company (IMC) platform.
Shareholders attending in-person and via the IMC platform will be able to raise questions with the Board of Directors in a Q&A session to be held immediately after the AGM.
As an added precaution to ensure the safety of in-person attendees, the AGM will conclude immediately following the Q&A session.
Shareholders are reminded that participation via the IMC platform will not constitute attendance at the AGM and those shareholders following the meeting via the IMC platform will not be able to vote on the day of the AGM - details on how to vote online are set out below.
Shareholders wishing to join the AGM remotely and participate in the Q&A session should register with IMC at: www.investormeetcompany.com/sareum-holdings-plc/register-investor. Shareholders who have already registered with IMC and requested to meet the Company will be invited automatically.
Questions can be submitted before the event via the IMC dashboard or at any time during the AGM via the "Ask a Question" function. Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market. Responses from the Q&A session will be published at the earliest opportunity on the IMC platform.
Voting
Shareholders are encouraged to vote electronically and to appoint the Chair of the AGM as their proxy.
Shareholders are requested to submit their votes online, no less than 48 hours before the time appointed for the meeting, via the shareholder portal at www.signalshares.com, where details of the procedures are set out. If shareholders have not done so already, they will need to register their account using their Investor Code, which can be found on their share certificate.
If shareholders hold shares in CREST and wish to vote via Signal Shares rather than the CREST electronic proxy appointment services, please contact the Company's registrars, Link Asset Services, to obtain their investor code.
Alternatively, shareholders may request a paper form of proxy from the Company's registrars, Link Asset Services, and details of how to contact them are set out in the Notice of AGM.
In order to vote online, shareholders will need to visit www.signalshares.com, search 'Sareum Holdings Plc' and use their Investor Code to log in or register. Once logged in, click the 'Vote Online Now' button and follow the procedure as instructed.
Posting of the Annual Report and Accounts and Notice of AGM
The Notice of AGM, along with a copy of the Company's Annual Report and Accounts for the year ended 30 June 2021, were posted on 19 November 2021 to those shareholders who requested a hard copy. A copy of both documents is available on the Company's website www.sareum.com.
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO
|
01223 497 700 |
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
Peel Hunt LLP (Joint Corporate Broker) James Steel
|
020 7418 8900 |
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
MEDiSTRAVA Consulting (Financial PR) Mark Swallow / David Dible |
020 7638 9571 |
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -